Email from Investors Relations:
Biomoda, Inc. to me
April 27, 2011
12:10 PM (4 minutes ago)
Dear Mr. Xxxxx:
As you know, one cannot always predict the outcome of research. Having said that, we are looking at a timeframe of six to nine months for completion of the optimization work currently underway on the CyPath assay. We will keep our investors and the public informed of our progress by releasing press releases when appropriate and posting the monthly President's Column on the Biomoda website.
The pilot study demonstrated proof of concept and we continue to believe that the CyPath molecular marker technology holds significant promise in the ongoing battle against lung cancer. Thank you for your interest in Biomoda's progress and your support for the company.
Best regards,
Julie Anne Overton
Investor Relations
News 
Market Data 
Discover 
AI
